...
首页> 外文期刊>Biotechnology and Bioengineering >Determination and control of low-level amino acid misincorporation in human thioredoxin protein produced in a recombinant Escherichia coli production system
【24h】

Determination and control of low-level amino acid misincorporation in human thioredoxin protein produced in a recombinant Escherichia coli production system

机译:重组大肠杆菌生产系统中生产的人硫氧还蛋白蛋白中低水平氨基酸错配的测定和控制

获取原文
获取原文并翻译 | 示例

摘要

Escherichia coli is used extensively in the production of proteins within biotechnology for a number of therapeutic applications. Here, we discuss the production and overexpression of the potential biopharmaceutical human thioredoxin protein (rhTRX) within E. coli. Overexpression of foreign molecules within the cell can put an enormous amount of stress on the translation machinery. This can lead to a misfiring in the construction of a protein resulting in populations differing slightly in amino acid composition. Whilst this may still result in a population of active molecules being expressed, it does present significant problems with molecules that are destined for clinical applications. Amino acid misincorporation of this subset could potentially result in antibodies being raised to these unnatural proteins. Cross-reaction with a patient's endogenous thioredoxin could then lead to an autoimmune phenomena and serious health implications. Generally, the issue of misincorporation appears not to be a routine regulatory concern (see ICH Q6B guidelines). Therefore, amino acid misincorporation may not have been detected, much less explored in the clinic as the occurrence or absence of these random errors is not routinely reported. Using current technologies based on proteomics, the ability to find misincorporation critically depends upon the criteria for matching theoretical and experimental mass spectrometry data. Additionally, isolation and extraction of these mistranslated proteins from the production process is both difficult and expensive. Therefore, it is advantageous to find routes for removing their production during the upstream phase. In this study, we show how modern proteomic technology can be used to identify and quantify amino acid misincorporation. Using these techniques we have shown how manipulation of gene sequence and scoping of fermentation media composition can lead to the reduction and elimination of these misincorporations in rhTRX.
机译:大肠埃希氏菌广泛用于生物技术领域的蛋白质生产中,可用于多种治疗应用。在这里,我们讨论了大肠杆菌中潜在的生物药物人硫氧还蛋白蛋白(rhTRX)的产生和过表达。细胞内外来分子的过度表达会给翻译机制带来巨大压力。这可能导致蛋白质构建错误,导致种群的氨基酸组成略有不同。尽管这仍然可能导致大量的活性分子被表达,但它确实给用于临床的分子带来了严重的问题。该子集的氨基酸错误掺入可能会导致产生针对这些非天然蛋白质的抗体。与患者内源性硫氧还蛋白的交叉反应可能导致自身免疫现象并严重影响健康。通常,错误合并的问题似乎不是常规的监管问题(请参阅ICH Q6B指南)。因此,可能没有检测到氨基酸错误掺入,在临床上很少进行探讨,因为没有常规报道这些随机错误的发生或不存在。使用基于蛋白质组学的当前技术,发现错误掺入的能力关键取决于匹配理论和实验质谱数据的标准。另外,从生产过程中分离和提取这些错误翻译的蛋白质既困难又昂贵。因此,有利的是找到用于在上游阶段去除其生产的路线。在这项研究中,我们展示了如何使用现代蛋白质组学技术来鉴定和定量氨基酸错误掺入。使用这些技术,我们已经证明了操纵基因序列和确定发酵培养基组成的范围如何减少和消除rhTRX中的这些错误掺入。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号